Sidoti Csr Issues Positive Forecast for USNA Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Research analysts at Sidoti Csr increased their Q3 2026 earnings per share estimates for USANA Health Sciences in a report issued on Thursday, January 15th. Sidoti Csr analyst A. Lebiedzinski now anticipates that the company will post earnings per share of $0.54 for the quarter, up from their previous forecast of $0.50. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q4 2026 earnings at $0.58 EPS and FY2026 earnings at $1.95 EPS.

Other equities research analysts have also issued reports about the company. Wall Street Zen lowered USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, December 29th. Finally, Zacks Research lowered shares of USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 7th. Two research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $36.00.

USANA Health Sciences Stock Performance

Shares of NYSE:USNA opened at $21.96 on Monday. The company has a market capitalization of $401.34 million, a PE ratio of 24.95, a price-to-earnings-growth ratio of 0.94 and a beta of 0.65. The stock has a fifty day moving average of $19.90 and a 200-day moving average of $25.14. USANA Health Sciences has a one year low of $18.48 and a one year high of $38.32.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Wednesday, October 22nd. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.62). The business had revenue of $213.67 million during the quarter, compared to analyst estimates of $224.97 million. USANA Health Sciences had a return on equity of 6.97% and a net margin of 1.86%.

Insider Buying and Selling

In other news, Director John Turman Fleming sold 1,750 shares of USANA Health Sciences stock in a transaction that occurred on Friday, October 31st. The shares were sold at an average price of $19.79, for a total value of $34,632.50. Following the transaction, the director owned 4,565 shares of the company’s stock, valued at $90,341.35. This trade represents a 27.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Frederic J. Winssinger sold 2,000 shares of USANA Health Sciences stock in a transaction on Monday, November 10th. The stock was sold at an average price of $19.21, for a total transaction of $38,420.00. Following the completion of the transaction, the director owned 5,986 shares in the company, valued at $114,991.06. This trade represents a 25.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 5,680 shares of company stock worth $114,090 in the last 90 days. 0.63% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On USANA Health Sciences

A number of hedge funds have recently bought and sold shares of the company. Two Sigma Investments LP increased its holdings in shares of USANA Health Sciences by 349.8% during the 3rd quarter. Two Sigma Investments LP now owns 160,933 shares of the company’s stock worth $4,434,000 after purchasing an additional 125,158 shares during the period. Pzena Investment Management LLC grew its position in USANA Health Sciences by 9.4% during the second quarter. Pzena Investment Management LLC now owns 1,198,260 shares of the company’s stock worth $36,583,000 after buying an additional 103,074 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in USANA Health Sciences by 202.3% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 97,537 shares of the company’s stock valued at $2,978,000 after acquiring an additional 65,268 shares during the period. Ameriprise Financial Inc. increased its stake in USANA Health Sciences by 64.6% during the second quarter. Ameriprise Financial Inc. now owns 150,090 shares of the company’s stock valued at $4,582,000 after acquiring an additional 58,921 shares during the period. Finally, Vanguard Group Inc. raised its holdings in USANA Health Sciences by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock valued at $29,452,000 after acquiring an additional 57,249 shares in the last quarter. 54.25% of the stock is currently owned by institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.